Investing.com -- 在欧盟委员会批准Zenrelia(一种每日一次口服治疗犬过敏性皮炎的药物)后,艾兰可动物健康(NYSE:ELAN)股票上涨2.6%。 这一批准代表着艾兰可在欧洲宠物健康产品组合的重大扩展,该公司将Zenrelia描述为其"增长最快的产品"。这种含有活性成分ilunocitinib的药物旨在控制与过敏性皮炎相关的瘙痒,并治疗12个月龄及以上犬只的特应性皮炎。 作为...
Source LinkInvesting.com -- 在欧盟委员会批准Zenrelia(一种每日一次口服治疗犬过敏性皮炎的药物)后,艾兰可动物健康(NYSE:ELAN)股票上涨2.6%。 这一批准代表着艾兰可在欧洲宠物健康产品组合的重大扩展,该公司将Zenrelia描述为其"增长最快的产品"。这种含有活性成分ilunocitinib的药物旨在控制与过敏性皮炎相关的瘙痒,并治疗12个月龄及以上犬只的特应性皮炎。 作为...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.